Could impurities in Enalapril blood pressure tablets pose health risks?
The U.S. Food and Drug Administration (FDA) has announced a Class II recall of a commonly prescribed blood pressure medication after the drug failed impurity and degradation testing. The recall affects thousands of enalapril maleate tablets distributed across the United States.
Should You Be Concerned About Enalapril Maleate Tablets USP?
According to the FDA, the recalled medication includes 675 bottles of Enalapril Maleate Tablets USP, 20 mg, packaged in 1,000-count bottles. The affected lot number is GEH25023, with an expiration date of June 30, 2027. The recall was initiated voluntarily on April 23 by manufacturer Unique Pharmaceutical Laboratories, a division of J.B. Chemicals & Pharmaceuticals based in India. The tablets were distributed nationwide by New Jersey-based Rising Pharma Holdings.
Enalapril () belongs to a class of medicines known as ACE inhibitors, which are widely used to treat high blood pressure and congestive heart failure. The drug is also marketed under the brand name Vasotec. The drug helps relax and widen blood vessels to improve blood flow and lower blood pressure.
Doctors widely use the drug to treat high blood pressure, congestive heart failure, and certain heart conditions such as left ventricular dysfunction, where the heart does not pump efficiently.
By reducing strain on the heart, Enalapril may also help lower the risk of heart attacks, strokes, and kidney complications linked to uncontrolled hypertension. The medication is also marketed under the brand name Vasotec and is available in different tablet strengths.
FDA officials stated that the recall was triggered after the medication failed an Organic Impurities Test, raising concerns about product quality and degradation. Although the agency classified the event as a Class II recall, meaning exposure could potentially cause temporary or medically reversible health consequences, no patient injuries or serious adverse events have been reported so far.
Why Blood Pressure Drug Recalls Are Raising Safety Concerns
Health experts note that impurities in medications can develop during manufacturing, storage, or chemical degradation over time. Drug recalls linked to contamination or dosage problems have become an increasing concern globally in recent years, particularly among blood pressure medications. Previous recalls involving drugs such as valsartan, losartan, irbesartan, and ramipril were tied to carcinogenic impurities or packaging errors.
Patients currently taking enalapril are advised not to stop their medication abruptly without consulting a healthcare professional, as uncontrolled hypertension can significantly increase the risk of heart attack, stroke, and kidney damage. Individuals with tablets from the affected lot should contact their pharmacist or healthcare provider for guidance on replacement or disposal.
The FDA continues to monitor drug quality issues and encourages healthcare professionals and consumers to report adverse reactions or quality concerns through the agency’s MedWatch reporting system.
References:
- How and when to take enalapril – (https://www.nhs.uk/medicines/enalapril/how-and-when-to-take-enalapril/)
Source-Medindia